Breaking News Instant updates and real-time market news.

ZTS

Zoetis

$84.06

-0.37 (-0.44%)

09:06
05/15/18
05/15
09:06
05/15/18
09:06

Anatara announces exclusive global license agreement with Zoetis

Anatara Lifesciences announced an exclusive licensing agreement with Zoetis for the worldwide development, manufacture, distribution and marketing of Detach as a non-antibiotic approach to aid in the control of diarrhoeal disease in livestock and in horses. Under the terms of the license agreement, Anatara has granted Zoetis exclusive rights to develop, manufacture, distribute and market Detach worldwide, including in Australia. The agreement follows an initial Exclusive Research Evaluation and License Option period, during which time Zoetis evaluated Detach for use as a non-antibiotic product in livestock species. The terms of the agreement include an upfront payment, milestone payments and royalties based on product sales. Intellectual property exclusively licensed to Zoetis under the agreement shall remain the sole property of Anatara. Exact details of the agreement remain confidential.

  • 15

    May

  • 12

    Jun

ZTS Zoetis
$84.06

-0.37 (-0.44%)

04/19/18
SBSH
04/19/18
NO CHANGE
Target $98
SBSH
Buy
Zoetis price target raised to $98 from $85 at Citi
Citi analyst Liav Abraham remains constructive on shares of Zoetis despite the stock's share price appreciation this year. The analyst raised her price target for the stock to $98 from $85 and maintains a Buy rating on the name. Abraham expects 2018 to be another year of "strong commercial execution" in both the livestock and companion segments of the business. She also sees potential for inorganic growth given Zoetis's "balance sheet optionality."
04/19/18
HDLY
04/19/18
DOWNGRADE
HDLY
Neutral
Zoetis downgraded to Neutral on valuation at Hilliard Lyons
Hilliard Lyons analyst Kurt Kemper downgraded Zoetis to Hold from Buy and maintained a $91 price target "strictly" due to valuation.
04/25/18
DBAB
04/25/18
NO CHANGE
DBAB
Hold
Merck may need to reassess animal health unit, says Deutsche Bank
While Merck (MRK) describes its animal health unit as a key growth driver and an important part of the company, it remains to be seen whether investors will continue to accept this as a reason for the business to remain within the company, Deutsche Bank analyst Gregg Gilbert tells investors in a research note. He believes the unit is potentially undervalued. Given Zoetis' (ZTS) success as a company and a stock, and Eli Lilly's (LLY) ongoing review of strategic options for its Elanco Animal Health business, Gilbert conducted a preliminary separation analysis of Merck's animal health unit. The analysis suggests that a separation could be meaningfully accretive to earnings. The analyst keeps a Hold rating on Merck.
04/25/18
CHLM
04/25/18
NO CHANGE
Target $94
CHLM
Buy
Zoetis price target raised to $94 from $87 at Craig-Hallum
Craig-Hallum analyst Kevin Ellich raised his price target for Zoetis to $94 from $87 as he expects "solid" Q1 results despite harsh weather conditions and tougher companion animal comps. The analyst reiterates a Buy rating on the shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.